SELLAS Life Sciences Group (SLS) News Today → This unknown company solves the biggest issue with AI (From Manward Press) (Ad) Free SLS Stock Alerts $1.47 +0.10 (+7.30%) (As of 05/15/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 15 at 8:10 PM | marketbeat.comSELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Short Interest Up 23.3% in AprilSELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) saw a significant growth in short interest during the month of April. As of April 30th, there was short interest totalling 6,990,000 shares, a growth of 23.3% from the April 15th total of 5,670,000 shares. Based on an average daily volume of 1,520,000 shares, the days-to-cover ratio is presently 4.6 days.May 14 at 11:16 PM | msn.comSLS Stock Earnings: SELLAS Life Sciences Gr Misses EPS for Q1 2024May 14 at 4:05 PM | globenewswire.comSELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 9, 2024 | americanbankingnews.comSELLAS Life Sciences Group (NASDAQ:SLS) Shares Down 3% May 7, 2024 | seekingalpha.comSLS SELLAS Life Sciences Group, Inc.May 3, 2024 | msn.comSamsung's Life Science Fund invests in Seattle's Latus BioMay 2, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: SELLAS Life Sciences Group (SLS) and NovoCure (NVCR)May 1, 2024 | msn.comSellas reports positive Phase 2 data from AML study, files for patentMay 1, 2024 | markets.businessinsider.comSELLAS Reports Positive Phase 2 Preliminary Data With SLS009May 1, 2024 | globenewswire.comSELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose LevelApril 29, 2024 | globenewswire.comSELLAS Life Sciences Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 StudyApril 27, 2024 | msn.comMahindra Lifespace's FY24 Profit Inches Down to Rs 98 Crore Amidst Record Sale Bookings of Rs 2,328 CroreApril 19, 2024 | seekingalpha.comSellas Life Sciences Group: A Lottery Ticket With An Estimated 9x PayoutMarch 28, 2024 | msn.comSELLAS Life Sciences Group files for $200M mixed shelfMarch 28, 2024 | globenewswire.comSELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate UpdateMarch 27, 2024 | markets.businessinsider.comBuy Rating for SELLAS Life Sciences Amid Positive AML Study Results and Strengthened FinancialsMarch 26, 2024 | markets.businessinsider.comSELLAS Phase 2a Study Of SLS009 In R/r AML Positive; Updates Phase 3 REGAL StudyMarch 26, 2024 | globenewswire.comSELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL StudyMarch 21, 2024 | wsj.comSELLAS Life Sciences Group Inc.March 19, 2024 | globenewswire.comSELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq RulesMarch 19, 2024 | globenewswire.comSELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ETMarch 16, 2024 | marketwatch.comSellas Life Sciences Shares Drop 31% After Direct Offering PricesMarch 15, 2024 | msn.comGeron, Graphite Bio, Immuneering among healthcare moversMarch 15, 2024 | msn.comSELLAS Life Sciences looks to raise $20M in a direct offeringMarch 15, 2024 | markets.businessinsider.comSellas Announces $20 Mln Registered Direct Offering, Concurrent Private PlacementMarch 15, 2024 | finance.yahoo.comSELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq RulesMarch 15, 2024 | globenewswire.comSELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq RulesMarch 12, 2024 | seekingalpha.comAadi Bioscience Q4 2023 Earnings PreviewMarch 10, 2024 | investing.comSellas Life Sciences Group Inc (SLS)March 9, 2024 | finanznachrichten.deSELLAS Life Sciences Group, Inc.: SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization PartnershipsMarch 8, 2024 | globenewswire.comSELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization PartnershipsMarch 7, 2024 | finance.yahoo.comSLS Mar 2024 4.000 putMarch 1, 2024 | finance.yahoo.comSELLAS Life Sciences Group, Inc. (SLS)March 1, 2024 | globenewswire.comSELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) ConferenceFebruary 29, 2024 | globenewswire.comSELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference: Updated Date and TimeFebruary 22, 2024 | morningstar.comSELLAS Life Sciences Group IncFebruary 16, 2024 | ca.finance.yahoo.comSLS Feb 2024 0.500 callFebruary 6, 2024 | finanznachrichten.deSELLAS Life Sciences Group, Inc.: SELLAS Announces Publication of Preclinical Data on its Highly Selective CDK9 Inhibitor, SLS009, in OncotargetFebruary 6, 2024 | finance.yahoo.comSELLAS Announces Publication of Preclinical Data on its Highly Selective CDK9 Inhibitor, SLS009, in OncotargetFebruary 1, 2024 | news.yahoo.comTesla sued for allegedly mishandling hazardous waste in California for yearsJanuary 25, 2024 | finance.yahoo.comSELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) ConferenceJanuary 11, 2024 | msn.comSellas Life Sciences gains on securing orphan drug status for r/r PTCL treatmentJanuary 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for SELLAS Life Sciences Amidst Promising Drug Development and Strategic FinancingJanuary 9, 2024 | msn.comSellas Life Sciences gains after leukemia therapy gets FDA fast track statusJanuary 9, 2024 | finance.yahoo.comSELLAS Life Sciences Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia PatientsJanuary 4, 2024 | markets.businessinsider.comSELLAS Life Sciences Prices Share Offering To Raise $9 Mln; Stock Tanks 35%January 4, 2024 | finance.yahoo.comSELLAS Life Sciences Announces Pricing of $9.0 Million Public OfferingJanuary 4, 2024 | msn.comWhy Is Sellas Life Sciences (SLS) Stock Down 25% Today?January 4, 2024 | msn.comSELLAS Life Sciences announces launch of proposed public offeringJanuary 3, 2024 | markets.businessinsider.comSELLAS Life Sciences Reports Proposed Public Offering Get SELLAS Life Sciences Group News Delivered to You Automatically Sign up to receive the latest news and ratings for SLS and its competitors with MarketBeat's FREE daily newsletter. Email Address With revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radar (Ad)Revolutionizing communication is what this NASDAQ-traded next-gen solution provider is doing. See how this company is well-positioned to capitalize in 2024 SLS Media Mentions By Week SLS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SLS News Sentiment▼0.340.55▲Average Medical News Sentiment SLS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SLS Articles This Week▼71▲SLS Articles Average Week Get SELLAS Life Sciences Group News Delivered to You Automatically Sign up to receive the latest news and ratings for SLS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Affimed News vTv Therapeutics News Cue Biopharma News Assembly Biosciences News Rallybio News BioXcel Therapeutics News Jaguar Health News Hookipa Pharma News Tempest Therapeutics News SCYNEXIS News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SLS) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market InsidersAmazon's betting big on this unknown AI companyManward PressThis Wall Street stock prediction just went viralChaikin AnalyticsWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaProtect Your Bank Account Before It’s Too LateWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SELLAS Life Sciences Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
